display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
immune chekpoint inhibitors
anti-PD-(L)1
cemiplimab EMPOWER lung1 ...
durvalumab based treatment
durvalumab alone MYSTIC ...
sintilimab based treatment
sintillimab plus SoC ORIENT-11
Immune checkpoint association
durvalumab plus tremelimumab MYSTIC ...
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC CheckMate 9LA

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons